Equities

R1 RCM Inc

R1 RCM Inc

Actions
Health CareHealth Care Providers
  • Price (USD)14.15
  • Today's Change-0.03 / -0.21%
  • Shares traded3.49m
  • 1 Year change-11.56%
  • Beta0.8528
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform0
Hold13
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for R1 Rcm Inc have a median target of 14.30, with a high estimate of 17.00 and a low estimate of 14.00. The median estimate represents a 1.06% increase from the last price of 14.15.
High20.1%17.00
Med1.1%14.30
Low-1.1%14.00

Earnings history & estimates in USD

On Aug 07, 2024, R1 Rcm Inc reported 2nd quarter 2024 losses of -0.02 per share. This result was in line with the consensus of the 13 analysts following the company and under-performed last year's 2nd quarter results by -0.02.
The next earnings announcement is expected on Nov 02, 2024.
Average growth rate+25.00%
R1 Rcm Inc reported annual 2023 earnings of 0.01 per share on Feb 27, 2024.
Average growth rate+91.40%
More ▼

Revenue history & estimates in USD

R1 RCM Inc. had 2nd quarter 2024 revenues of 627.90m. This missed the 633.48m consensus estimate of the 15 analysts following the company. This was 15.08% above the prior year's 2nd quarter results.
Average growth rate+2.89%
R1 RCM Inc. had revenues for the full year 2023 of 2.25bn. This was 24.79% above the prior year's results.
Average growth rate+17.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.